Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by TradeToFreedomon Jul 31, 2020 7:34am
262 Views
Post# 31348263

Insider holdings

Insider holdings Just to clear this up, largest holding are by two board of directors both with substantial common share count Wu, Yung Cheng 1.6m as of last reporting 2019/10/03 Macnee, Walter Minnes 4.3M as of last reporting 2019/10/03 And as far as Dan and wallace as follows: Insider Name: Legault, Daniel Marcel Insider Relationship: 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer 2020-06-04 Common Shares 300,00 2018-04-20 Common Shares Schmed Enterprises Inc. 296,666 2020-06-01 Options (Common Shares) 3,380,206 2019-11-28 Restricted Share Units (Common Shares)6,790,000 2019-08-13 Warrants (Common Shares 57,500 2019-06-01 Warrants (Common Shares)Schmed Enterprises Inc. 0 Insider Name: Wallace, John Lawrence Insider Relationship: 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer 2020-06-04 Common Shares 276,770 2020-06-04 Common Shares AltaPharm International Inc. 400,000 2020-06-01 Options (Common Shares) 3,100,000 2019-11-28 Restricted Share Units (Common Shares) 6,050,000 2018-03-27 Warrants (Common Shares) 0 2019-06-01 Warrants (Common Shares)AltaPharm International Inc. 0
Bullboard Posts